In Brief: More St. Jude
This article was originally published in The Gray Sheet
Executive SummaryMore St. Jude: Firm's Pacesetter division gains FDA clearance to market its Tendril 1188K lead. The lead is a unipolar version of the firm's 1188T bipolar lead, cleared by FDA last fall. The company says the Tendril 1188K is "two to four times more lubricious than conventional polyurethane leads" due to its Fast-Pass molecular coating...
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.